Objective  To explore the effects of different doses of rosuvastatin on ventricular remodeling, cardiac function and serum lipids in patients with acute myocardial infarction after coronary intervention.

Methods  Patients who received coronary intervention in The Affiliated Hospital of Inner Mongolia Medical University from April 2021 to April 2023 were selected as research subjects. The patients were divided into low-dose group, medium-dose group and high-dose group according to the drug dosage after admission. Patients in each group were treated with conventional drugs such as aspirin and clopidogrel. The low-dose group, the middle-dose group and the high-dose group took 5 mg, 10 mg and 20 mg of rosuvastatin before going to bed on the basis of conventional drug treatment, respectively. Cardiac function was assessed by echocardiography before and after treatment, and left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF) were recorded. Ventricular remodeling was assessed by fasting static serum C-reactive protein (CRP), matrix metalloproteinase-9 (MMP-9), and brain natriuretic peptide (BNP). The fasting static serum total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) of patients in each group were detected to evaluate the influence on serum lipids. Serum tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were measured before and after treatment to evaluate the inflammatory response.

Results  A total of 120 patients were included, with 40 cases in each group. After treatment, the differences in levels of LVEDD, LVESD, LVEDV, LVESV, (LVEF), CRP, MMP-9, BNP, TC, TG, LDL-C, TNF-α and IL-6 were statistically significant among the three groups (P<0.05). Compared with low-dose and medium-dose groups, the levels of LVEDD, LVESD, LVEDV, LVESV, CRP, MMP-9, BNP, TC, TG, LDL-C, TNF-α and IL-6 in high-dose group were significantly decreased, while the levels of LVEF were significantly increased (P<0.05).

Conclusion  Different doses of rosuvastatin have different effects on ventricular remodeling, cardiac function and serum lipid in patients with acute myocardial infarction after coronary intervention. Prophylactic remodeling with a dose of 20 mg·d^-1 improved cardiac function better than the commonly used dosage of 5 mg·d^-1 and 10 mg·d^-1.

1.Sasko B, Jaehn P, Müller R, et al. Understanding the importance of social determinants and rurality for the long-term outcome after acute myocardial infarction: study protocol for a single-centre cohort study[J]. BMJ Open, 2022, 12(4): e056888. DOI: 10.1136/bmjopen-2021-056888

2.Hoole SP, Bambrough P. Recent advances in percutaneous coronary intervention[J]. Heart, 2020, 106(18): 1380-1386. DOI: 10.1136/heartjnl-2019-315707.

3.Tucker B, Vaidya K, Cochran BJ, et al. Inflammation during percutaneous coronary intervention-prognostic value, mechanisms and therapeutic targets[J]. Cells, 2021, 10(6): 1391-1394. DOI: 10.3390/cells10061391.

4.Cerrato E, Giacobbe F, Quadri G, et al. Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry[J]. Eur Heart J, 2021, 42(33): 3161-3171. DOI: 10.1093/eurheartj/ehab372.

5.Park MW, Kim CJ, Kim MC, et al. A prospective, multicenter, randomized, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilized patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALOS-AMI trial[J]. Euro Intervention, 2021, 16(14): 1170-1176. DOI: 10.4244/EIJ-D-20-00187.

6.He W, Cao M, Li Z. Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) [J]. Drug Dev Res, 2020, 81(5): 551-556. DOI: 10.1002/ddr.21651.

7.中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10): 766-783. DOI: 10.3760/cma.j.issn. 0253-3758.2019.10.003.

8.Leone AM, Galante D, Siudak Z. Lipoprotein(a): the hidden side of the Moon? Prognostic role of lipoprotein(a) in PCI-AMI patients[J]. Minerva Cardiol Angiol, 2023, 16(5): 21-25. DOI: 10.23736/S2724-5683.22.06271-8.

9.Kim CH, Han KA, Yu J, et al. Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia, a Randomized, Double-blind, and Placebo-controlled Trial[J]. Clin Ther, 2018, 40(1): 83-94. DOI: 10.1016/j.clinthera.2017.11.007.

10.Bao J, Kan R, Chen J, et al. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials[J]. Pharmacol Res, 2021, 169(56): 105573. DOI: 10.1016/j.phrs.2021.105573.

11.Fedulaev Y, Makarova I, Pinchuk T. Fragmented QRS as a marker of coronary atherosclerosis severity evaluated by the Gensini score[J]. Ann Cardiol Angeiol (Paris), 2021, 70(3): 143-147. DOI: 10.1016/j.ancard.2021.03.001.

12.刘宇宏. 羟甲基戊二酰辅酶A还原酶抑制剂抗心室重塑作用及其机制的研究[D]. 武汉: 华中科技大学, 2005.

13.Miao Y, Liu Y, Liu C, et al. Diagnostic Value of Echocardiography Combined with Serum h-FABP and cTnI in Myocardial Infarction and Its Evaluation Value in Left Ventricular Function[J]. Evid Based Complement Alternat Med, 2022, 5(24)8809708. DOI: 10.1155/2022/8809708.

14.肖新怀, 徐米清, 方燕龄, 等. 丹红注射液联合瑞舒伐他汀抗冠状动脉粥样硬化的作用机制研究[J].国际医药卫生导报, 2019, 25(20): 5-7. [Xiao XH, Xu MQ, Fang YL, et al. Mechanism for role of Danhong injection combined with rosuvastatin in patients with coronary atherosclerosis[J]. International Medicine and Health Guidance News, 2019, 25(20): 5-7.] DOI: 10.3760/cma.j.issn.1007-1245.2019.20.016.

15.Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6[J]. Nat Rev Cardiol, 2021, 18(1):58-68. DOI: 10.1038/s41569-020-0431-7.

16.Bouchareychas L, Duong P, Covarrubias S, et al. Macrophage Exosomes Resolve Atherosclerosis by Regulating Hematopoiesis and Inflammation via MicroRNA Cargo[J]. Cell Rep, 2020, 32(2): 107881. DOI: 10.1016/j.celrep.2020.107881.

17.Oprescu N, Micheu MM, Scafa-Udriste A, et al. Inflammatory markers in acute myocardial infarction and the correlation with the severity of coronary heart disease[J]. Ann Med, 2021, 53(1): 1041-1047. DOI: 10.1080/07853890. 2021.1916070.

18.Alizadeh P, Bahramali E, Hedayati A, et al. Anticipation of high-sensitivity C-reactive protein effect on post myocardial infarction depression disorder[J]. Galen Med J, 2021, 28(10): e1512. DOI: 10.31661/gmj.v10i0.1512.

19.Nordeng J, Schandiz H, Solheim S, et al. TIMP-1 expression in coronary thrombi associate with myocardial injury in ST-elevation myocardial infarction patients[J]. Coron Artery Dis, 2022, 33(6): 446-455. DOI: 10.1097/MCA. 0000000000001128.

20.Kong W, Ma J, Lin Y, et al. Positive association of plasma trimethylamine-n-oxide and atherosclerosis in patient with acute coronary syndrome[J]. Cardiovasc Ther, 2022, 2022: 2484018. DOI: 10.1155/2022/2484018.